Name | 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid |
---|---|
Synonyms |
UNII-R3734K0M7L
Lidorestat IDD-676 3NA |
Description | Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used to treat chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation[1][2][3]. |
---|---|
Related Catalog | |
Target |
IC50: 5 nM (Rldose reductase)[1] |
In Vitro | From in vitro experiments, Lidorestat has a reported IC50 against recombinant human aldose reductase (/h/-ALR2) of 5 μM. Against recombinant human aldehyde reductase (/h/-ALR1), Lidorestat has a reported IC50 of 27,000 μM, yielding a selectivity of /h/-ALR1//h/-ALR2 of 5400:1[1][2]. |
In Vivo | Lidorestat (25 mg/kg/day; oral administration; twice daily; for 6 weeks; diabetic mice) treatment decreases fructose and reduces mortality in diabetic hAR-expressing mice. And Lidorestat does not affect weight[1]. Animal Model: Diabetic low-density lipoprotein (LDL) receptor-deficient [Ldlr(-/-)] mice[1] Dosage: 25 mg/kg/day Administration: Oral administration; twice daily; for 6 weeks Result: Diabetic hAR-expressing mice had decreased fructose and reduced mortality. |
References |
Density | 1.55g/cm3 |
---|---|
Boiling Point | 591.4ºC at 760 mmHg |
Melting Point | 177-178 °C |
Molecular Formula | C18H11F3N2O2S |
Molecular Weight | 376.35200 |
Flash Point | 311.4ºC |
Exact Mass | 376.04900 |
PSA | 83.36000 |
LogP | 4.34370 |
Vapour Pressure | 7.87E-15mmHg at 25°C |
Index of Refraction | 1.681 |
Storage condition | 2-8°C |